Click on one of these terms to refine your search
1 to 10 of 60 literature results
BACKGROUND: Any benefit of adjuvant interferon alfa-2b for melanoma could depend on dose and duration of treatment. Our aim was to determine whether p…
Authors: Alexander M M Eggermont, Stefan Suciu, Mario Santinami, Alessandro Testori, Wim H J Kruit, Jeremy Marsden, Cornelis J A Punt, François Salès, Martin Gore, Rona Mackie,…
Source: Lancet. 2008 Jul 12
View Full TextBACKGROUND: Appearance of autoantibodies and clinical manifestations of autoimmunity in melanoma patients treated with adjuvant interferon (IFN)-alpha…
Authors: Marna G Bouwhuis, Stefan Suciu, Sandra Collette, Steinar Aamdal, Wim H Kruit, Lars Bastholt, Ulrika Stierner, François Salès, Poulam Patel, Cornelis J A Punt,…
Source: Journal of the National Cancer Institute. 2009 Jun 16
View Full TextDisease-free survival is increasingly being used as the primary endpoint of most trials testing adjuvant treatments in cancer. Other frequently used e…
Authors: Cornelis J A Punt, Marc Buyse, Claus-Henning Köhne, Peter Hohenberger, Roberto Labianca, Hans J Schmoll, Lars Påhlman, Alberto Sobrero, Jean-Yves Douillard
Source: Journal of the National Cancer Institute. 2007 Jul 4
View Full TextAuthors: Matthew T Seymour, Cornelis J A Punt
Source: Lancet. 2007 Dec 8
View Full TextC-type lectin receptors (CLRs) fulfill multiple functions within the immune system by recognition of carbohydrate moieties on foreign or (altered) sel…
Authors: Friederike Meyer-Wentrup, Daniel Benitez-Ribas, Paul J Tacken, Cornelis J A Punt, Carl G Figdor, I Jolanda M de Vries, Gosse J Adema
Source: Blood. 2008 Apr 15
View Full TextEx vivo generated cancer vaccines based on dendritic cells (DCs) are currently applied in the clinic. The migration of DCs from the tissues to the lym…
Authors: Gosse J Adema, I Jolanda M de Vries, Cornelis J A Punt, Carl G Figdor
Source: Current opinion in immunology. 2005 Apr
View Full TextBACKGROUND: The optimum use of cytotoxic drugs for advanced colorectal cancer has not been defined. Our aim was to investigate whether combination tre…
Authors: Miriam Koopman, Ninja F Antonini, Joep Douma, Jaap Wals, Aafke H Honkoop, Frans L G Erdkamp, Robert S de Jong, Cees J Rodenburg, Gerard Vreugdenhil, Olaf J L Loosveld,…
Source: Lancet. 2007 Jul 14
View Full TextBACKGROUND: Individuals affected by melanoma with thick primary tumours or regional node involvement have a poor outlook, with only 30-50% alive at 5 …
Authors: Alexander M M Eggermont, Stefan Suciu, Rona MacKie, Wlodzimierz Ruka, Alessandro Testori, Wim Kruit, Cornelis J A Punt, Michelle Delauney, François Sales, Gerard Groenewegen,…
Source: Lancet. 2005 Oct 1
View Full TextThe success of cellular therapies will depend in part on accurate delivery of cells to target organs. In dendritic cell therapy, in particular, delive…
Authors: I Jolanda M de Vries, W Joost Lesterhuis, Jelle O Barentsz, Pauline Verdijk, J Han van Krieken, Otto C Boerman, Wim J G Oyen, Johannes J Bonenkamp, Jan B Boezeman, Gosse J Adema,…
Source: Nature biotechnology. 2005 Nov
View Full TextElectroporation of dendritic cells (DC) with mRNA encoding tumor-associated antigens (TAA) for cancer immunotherapy has been proved efficient and clin…
Authors: Danita H Schuurhuis, Pauline Verdijk, Gerty Schreibelt, Erik H J G Aarntzen, Nicole Scharenborg, Annemiek de Boer, Mandy W M M van de Rakt, Marieke Kerkhoff, Marie-Jeanne P Gerritsen, Femke Eijckeler,…
Source: Cancer research. 2009 Apr 1
View Full Text